Company intelligence / Profile preview

Harbour Lights

Ownership: Private
Development stage: Other

Overview

The company has advanced multiple clinical-stage assets in immunology and oncology using its proprietary antibody discovery platforms. Its lead asset batoclimab has reached NDA/BLA stage for myasthenia gravis. Other programs are in Phase 1–3 trials targeting autoimmune diseases and cancers.

Therapeutic areas: OphthalmologyNeurologyOncology
Modalities: Monoclonal antibodyBispecific monoclonal antibodyRecombinant proteinBiological products
Industry: Biotech

Partnerships

Multiple global pharmaceutical/biotech companies including BeiGene and over forty academic/industry partners leveraging its platform technologies.

Beyond the preview

Go deeper on Harbour Lights.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Harbour Lights.

Explore the full profile